MRK Merck & Company Inc. (new)

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 18 October 2019 Merck Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma

   Opinion Supports Use of KEYTRUDA, as Monotherapy or in Combination with Platinum and 5-Fluorouracil Chemotherapy, in Patients Whose Tumors Express PD-L (CPS ≥1) Merck (NYSE:MRK), known as MSD outside the United States

2. 18 October 2019 Merck Receives EU CHMP Positive Opinion for Investigational V920 Ebola Zaire Vaccine for Protection Against Ebola Virus Disease

   Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion

3. 10 October 2019 NexTech Appoints New Chief Financial Officer

   NEW YORK and TORONTO, Oct. 10, 2019 (GLOBE NEWSWIRE) -- NexTech AR Solutions (the "Company" or "NexTech") (OTCQB:NEXCF) (CSE:NTAR) (FSE: N29) is pleased to announce that it has appointed Kashif Malik as Chief Financial

4. 08 October 2019 BriaCell Therapeutics Corp. to File Amendment to Management Information Circular

   BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 08, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

5. 08 October 2019 Merck Issues 2018/2019 Corporate Responsibility Report

   Report Illustrates Merck's Approach to Long-Term Sustainability for Business and Society Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued its 2018/2019 Corporate Responsibility Report.

6. 07 October 2019 BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer

   Patient dosing has begun in the Phase I/IIa study evaluating the anti-tumor effects of BriaCell's lead candidate, Bria-IMT™ in combination with Incyte's INCMGA00012 and epacadostat in patients with advanced breast cancer.Cancer blocks the immune system pr

7. 02 October 2019 Merck's KEYTRUDA® (pembrolizumab) Now Approved as Monotherapy in China for First-Line Treatment of Certain Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1

   KEYTRUDA is First Anti-PD-1 Therapy Approved as Monotherapy and in Combination with Chemotherapy in First-Line Setting for NSCLC in China Merck (NYSE:MRK), known as MSD outside the United States and Canada, today

8. 02 October 2019 FDA Accepts Two Applications for Merck's DIFICID® (fidaxomicin) to Treat Children Aged Six Months Up to 18 years with Clostridium difficile Infections

   DIFICID® Pediatric Filings Receive Priority Review Classification Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for

9. 01 October 2019 BriaCell Therapeutics Corp. to Clarify Record Date

   BERKELEY, Calif. and VANCOUVER, British Columbia, Oct. 01, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

10. 01 October 2019 Merck to Hold Third-Quarter 2019 Sales and Earnings Conference Call on October 29

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2019 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, Oct. 29.

11. 01 October 2019 Note from Chairman of BriaCell Therapeutics – October is Breast Cancer Awareness Month

    BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 01, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

12. 30 September 2019 Eisai: Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress

    TOKYO, Oct 1, 2019 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A.

13. 30 September 2019 LYNPARZA® (olaparib) More Than Doubled Median Radiographic Progression-Free Survival (rPFS) in BRCA1/2 or ATM Metastatic Castration-Resistant Prostate Cancer vs. Standard of Care (7.4 vs. 3.6 months)

    Merck and AstraZeneca's LYNPARZA Reduced the Risk of Disease Progression or Death by 51% in Men with Homologous Recombination Repair (HRR) Gene Mutations First Positive Phase 3 Trial Evaluating a Targeted Treatment in

14. 30 September 2019 Companies Seek an Innovative Solution to the Growing Cancer Rates

    NEW YORK, Sept. 30, 2019 /PRNewswire/ -- Cancer is among the leading causes of death in the world as countries are burdened by a lack of access to adequate healthcare. In 2018, the World Cancer Research Fund (WCRF)

15. 30 September 2019 Merck to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Michael Nally, Chief Marketing Officer for Merck, is scheduled to present during a fireside chat at the Cantor Fitzgerald 2019

16. 30 September 2019 Pivotal RESTORE-IMI 2 Phase 3 Study of Merck's RECARBRIO™ (imipenem, cilastatin, and relebactam) in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Met Primary Endpoint

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 RECARBRIO™ (imipenem 500 mg, cilastatin 500 mg, and relebactam 250 mg) RESTORE-IMI 2 trial met its primary

17. 29 September 2019 Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage Triple-Negative Breast Cancer (TNBC)

    Interim Results from Pivotal Neoadjuvant/Adjuvant Phase 3 KEYNOTE-522 Trial Presented for the First Time at ESMO 2019 Congress During Presidential Symposium As Previously Announced, KEYTRUDA Plus Chemotherapy Has Been

18. 29 September 2019 Final Study Results Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Eisai today announced final results from the full endometrial cancer cohort of KEYNOTE-146/Study 111 evaluating KEYTRUDA, Merck's anti-PD-1

19. 28 September 2019 LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Significantly Increased Progression-Free Survival as First-Line Maintenance Treatment with Bevacizumab for Newly-Diagnosed Advanced Ovarian Cancer

    AstraZeneca and Merck's LYNPARZA Added to Bevacizumab Reduced the Risk of Disease Progression or Death by 41% in the Overall Trial Population of Women Who Responded to Platinum-Based Chemotherapy AstraZeneca and Merck

20. 25 September 2019 BriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special 'Targeted Immunotherapy' Issue in Prestigious Journals

    BERKELEY, Calif., and VANCOUVER, British Columbia, Sept. 25, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

21. 19 September 2019 BriaCell Announces Public Disclosure: Remarkable Responder in Combination Study of Lead Candidate with KEYTRUDA®

    Material information is being presented concurrent with this press release at 9:35am Eastern Time at the Next Gen Immuno-Oncology Congress.  Publicly-traded securities of BriaCell Therapeutics Corp.

22. 18 September 2019 Biotech Companies Endeavor to Address Global Health Issues

    NEW YORK, Sept. 18, 2019 /PRNewswire/ -- The global burden of diseases continues to grow each year, despite ongoing medical advancements. The Institute for Health Metrics and Evaluation (IHME) highlighted in a report

23. 18 September 2019 FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma

    Combination Treatment Approved for Patients with Advanced Endometrial Carcinoma That Is Not Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Who Have Disease Progression Following Prior Systemic Therapy and Are Not Candidates for Curative Surgery or Ra

24. 17 September 2019 FDA Approves KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma

    Combination Treatment Approved for Patients with Advanced Endometrial Carcinoma That Is Not Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR), Who Have Disease Progression Following Prior

25. 17 September 2019 FDA Accepts Merck's Biologics License Application (BLA) and Grants Priority Review for V920, the Company's Investigational Vaccine for Ebola Zaire Virus

    Merck Continues to Expand Investigational Supply to Support International Ebola Outbreak Response Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration

26. 10 September 2019 Merck Announces First Nine "Safer Childbirth Cities" Committed to Reducing Maternal Deaths and Narrowing Disparities in the US

    Co-Funders Join Merck for Mothers to Support Newly Formed City-Based Coalitions Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today its funding support of projects in nine cities

27. 10 September 2019 Pooled Analysis Continues to Show Merck's KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Patients with Advanced NSCLC Whose Tumors Do Not Express PD-L1

    Findings from Pooled Analysis of KEYNOTE-189, KEYNOTE-407 and KEYNOTE-021 (Cohort G) Presented at the IASLC 2019 World Conference on Lung Cancer Merck (NYSE:MRK), known as MSD outside the United States and Canada,

28. 09 September 2019 Pivotal New Data from Merck's Broad Oncology Portfolio at ESMO 2019 Congress

    Phase 3 Data for KEYTRUDA® (pembrolizumab) as Neoadjuvant Therapy in Combination with Chemotherapy in Patients with Triple-Negative Breast Cancer (KEYNOTE-522) to be Featured in ESMO Presidential Symposium and Official

29. 05 September 2019 Merck to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer, and Dr. Roger M. Perlmutter, president, Merck Research Laboratories,

30. 04 September 2019 Merck Foundation Launches Five-Year Initiative to Reduce Disparities in HIV Care for Vulnerable and Underserved Southeastern US Communities

    The Merck Foundation (the Foundation) has launched HIV Care Connect, a $7 million, five-year initiative to help reduce disparities in access to care and improve health outcomes for persons with HIV living in vulnerable

31. 04 September 2019 European Commission Approves Merck's KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC)

    European Approval Based on KEYNOTE-426 Trial Results Demonstrating Significant Improvement in Overall Survival with KEYTRUDA in Combination with Axitinib Compared to Sunitinib KEYTRUDA is First Anti-PD-1 Therapy

32. 22 August 2019 Merck Highlights New Data from Leading Lung Cancer Clinical Development Program at the IASLC 2019 World Conference on Lung Cancer

    Pooled Overall Survival (OS) Data from Three Trials with KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Subgroup of Patients with Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Do Not Express PD-L1 New KEYTRUDA